NEW YORK and TORONTO and HERZLIYA, Israel, April 25, 2023 (GLOBE NEWSWIRE) -- InterCure Ltd. (NASDAQ: INCR) (TSX: INCR.U) (TASE: INCR) (dba Canndoc) ("InterCure" or the "Company"), the leading medical ...
The Company reports NIS 130 million in revenue and NIS 12 million in positive operating cash flow, demonstrating resilience and sustained profitability with its eleventh consecutive half of positive ...
Revenues during the first half of 2024 reached NIS 126 million, alongside an Adjusted EBITDA 1 of NIS 21 million (Approximately 17% of revenues). Alexander Rabinovitch, CEO of InterCure noted: ...
NEW YORK and HERZLIYA, Israel , Oct. 31, 2023 (GLOBE NEWSWIRE) -- InterCure Ltd. (NASDAQ: INCR) (TASE: INCR) (dba Canndoc) ("InterCure" or the "Company"), the leading medical cannabis company in ...
InterCure reports preliminary estimated revenue of NIS 265 million for 2025 and positive Adjusted EBITDA, marking its twelfth consecutive half-year of positive Adjusted EBITDA. Revenue for 2025 ...
InterCure reports preliminary estimated revenue of NIS 265 million for 2025 and positive Adjusted EBITDA 2, marking its twelfth consecutive half-year of positive Adjusted EBITDA. Revenue for 2025 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results